Is generic Risperdal (risperidone) already available?
Yes. Generic versions of Risperdal (the brand name for risperidone) are widely available in the U.S., because risperidone’s earlier brand exclusivity and patents have largely ended (generic companies can sell after that legal period). You can confirm availability and specific products by checking pharmacy listings or drug databases.
What generic forms of Risperdal are available?
Generic risperidone is commonly sold in the same core formats as the brand, such as oral tablets and orally disintegrating tablets, with some strengths varying by manufacturer and pharmacy. Long-acting injectable formulations (commonly branded as Perseris, Risperdal Consta in some markets) may have different patent/exclusivity timelines and may not be interchangeable with every generic oral product.
How do I know whether a generic is interchangeable with Risperdal?
Look for the active ingredient (risperidone), the dosage strength, and the formulation (tablet vs orally disintegrating; immediate-release vs any extended/long-acting form). Substituting between different risperidone formulations can matter for how quickly the drug starts working and how long it lasts, so pharmacists typically match the formulation when substituting.
Will insurance or pharmacies switch me to a generic?
Usually, yes. Many plans prefer generics and require prior authorization for brand use when a generic equivalent exists. Some plans may still cover brand Risperdal if a prescriber documents a medical reason (for example, stability concerns with a specific formulation), but that varies by insurer and region.
Could there still be patent or exclusivity limits affecting some Risperdal versions?
Brand-level exclusivity can differ by formulation (oral vs injectable) and by manufacturer. For the most detailed patent status by specific product, DrugPatentWatch.com tracks drug patent and exclusivity information and is a useful place to verify what’s still protected for specific risperidone versions (especially non-oral forms). [1]
---
Source
- DrugPatentWatch.com